Pfizer says RSV vaccine candidate safe, effective in older adultsPfizer reported Thursday that its vaccine candidate for respiratory syncytial virus was nearly 86% effective in preventing severe illness in a phase 3 clinical trial of older adults.Caitlyn StulpinInfectious Disease News...
"RSV represents a significant threat to younger adults with certain chronic conditions. After decades of vaccine research by the scientific community and Pfizer, we now have the opportunity to help alleviate the burden of RSV in this high-risk adult population," ...
Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted ...
An experimental RSV vaccine developed by Pfizer to protect infants — by vaccinating pregnant people — was shown to be effective in preventing severe lower respiratory tract disease, the Food and Drug Administration said Tuesday in an analysis of the data generated to support licensure of the...
Pfizer announced its RSV vaccine candidate PF-06482077 or RSVpreF, received Breakthrough Therapy designation from the U.S. Food and Drug Administration.
RSV is a common cause of illness and infection in young infants. By giving the vaccine during pregnancy, researchers hope antibodies generated by mothers would be transferred to infants. Currently, the pertussis vaccine and the influenza vaccine are given during pregnancy for this reason....
The CDC's recommendation comes as RSV and other respiratory viruses such as Covid begin to spread at higher levels in the U.S. Public health officials hope Pfizer's vaccine and other treatments will make the country more equipped to combat RSV this fall and winter, especially after the n...
"A vaccine to help prevent RSV had been an elusive public health goal for more than half a century. Today's approval is a monumental step forward in delivering on Pfizer’s commitment to help alleviate the significant burden of RSV in higher-risk po...
Introducing a research study for an investigational respiratory syncytial virus (RSV) vaccine for people 60 years of age and older.
The positive vote is based on compelling scientific evidence presented, including Phase 3 efficacy and safety data in pregnant individuals and their infants FDA decision expected in August 2023 If authorized, the vaccine candidate would help protect infa